KOL Views: Reassessing CAR-T leaders in light of ASH data dump

All three of the leading CAR-T players reported updated results for their lymphoma therapies this week, with Novartis suggesting its Kymriah (tisagenlecleucel) is safer than Gilead Sciences’ Yescarta (axicabtagene ciloleucel) and Juno Therapeutics claiming its JCAR017 is safer than Kymriah. (See ViewPoints: Juno claims a niche position for JCAR017, only to find Novartis is already there.)

To provide FirstWord readers with rapid feedback on how the products appear to be stacking up and how broadly their safety profiles will likely allow them to be used, we are hosting an expert call with a key opinion leader (KOL) on December 18.

Key topics that will be discussed during the call include, among other things… feedback on the risk/benefit profiles of Kymriah, Yescarta and JCAR017; how differentiated is the safety profile of Yescarta versus Kymriah, and of JCAR017 relative to the other two; how concerning is the drop-off in JCAR017’s response rate; could one or more of these agents eventually be used in an outpatient setting; and what factor(s) will be most important in dictating which agent a physician decides to use?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the commercial prospects for this first wave of CAR-T therapies.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.